Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Mar 01, 2022

SELL
$31.38 - $48.47 $757,481 - $1.17 Million
-24,139 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$26.93 - $37.68 $650,063 - $909,557
24,139 New
24,139 $842,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.12B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Sante Capital Fund, LP Portfolio

Follow Sante Capital Fund, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sante Capital Fund, LP, based on Form 13F filings with the SEC.

News

Stay updated on Sante Capital Fund, LP with notifications on news.